These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30849056)

  • 1. Best Practices for Aripiprazole Lauroxil Administration: From Formulation Development to Injection Technique.
    Farwick S; Hickey MB; Jacobs G; Faldu SP; Vandiver J; Weiden PJ
    J Psychiatr Pract; 2019 Mar; 25(2):82-90. PubMed ID: 30849056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents.
    Aggarwal A; Gopalakrishna G; Lauriello J
    Clin Schizophr Relat Psychoses; 2016; 10(1):58-63. PubMed ID: 27074333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole Lauroxil: A Review in Schizophrenia.
    Frampton JE
    Drugs; 2017 Dec; 77(18):2049-2056. PubMed ID: 29177572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report.
    Eum S; Schneiderhan ME; Brown JT; Lee AM; Bishop JR
    BMC Psychiatry; 2017 Jul; 17(1):238. PubMed ID: 28673279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia.
    Hard ML; Mills RJ; Sadler BM; Turncliff RZ; Citrome L
    J Clin Psychopharmacol; 2017 Jun; 37(3):289-295. PubMed ID: 28350572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil.
    Risinger R; Hard M; Weiden PJ
    Psychopharmacol Bull; 2017 Aug; 47(3):26-34. PubMed ID: 28839337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
    Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
    CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
    Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
    J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia.
    Turncliff R; Hard M; Du Y; Risinger R; Ehrich EW
    Schizophr Res; 2014 Nov; 159(2-3):404-10. PubMed ID: 25266547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review.
    Rapinesi C; Kotzalidis GD; Mazzarini L; Brugnoli R; Ferracuti S; De Filippis S; Cuomo I; Giordano G; Del Casale A; Angeletti G; Sani G; Girardi P
    Clin Drug Investig; 2019 Aug; 39(8):713-735. PubMed ID: 31152368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
    Citrome L
    Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
    [No Abstract]   [Full Text] [Related]  

  • 13. Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia.
    Lauriello J; Weiden PJ; Gleeson CD; Shah A; Boulanger L; Jariwala-Parikh K; Hedgeman E; O'Sullivan AK
    CNS Drugs; 2021 Oct; 35(10):1123-1135. PubMed ID: 34546558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia.
    Hard ML; Wehr AY; Du Y; Weiden PJ; Walling D; von Moltke L
    J Clin Psychopharmacol; 2018 Oct; 38(5):435-441. PubMed ID: 30015676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.
    Ostuzzi G; Bertolini F; Del Giovane C; Tedeschi F; Bovo C; Gastaldon C; Nosé M; Ogheri F; Papola D; Purgato M; Turrini G; Correll CU; Barbui C
    Am J Psychiatry; 2021 May; 178(5):424-436. PubMed ID: 33596679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia.
    Jain R; Meyer J; Wehr A; Rege B; von Moltke L; Weiden PJ
    CNS Spectr; 2020 Jun; 25(3):323-330. PubMed ID: 31111801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents.
    Jann MW; Penzak SR
    CNS Drugs; 2018 Mar; 32(3):241-257. PubMed ID: 29569082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period.
    Weiden PJ; Du Y; Liu CC; Stanford AD
    CNS Spectr; 2019 Aug; 24(4):419-425. PubMed ID: 29941057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.
    Citrome L
    Expert Rev Neurother; 2017 Oct; 17(10):1029-1043. PubMed ID: 28832262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.